Summary
BeiGene Ltd. (ONC) demonstrated strong revenue growth in 2024, reaching $3.8 billion, a significant increase from the prior year, driven primarily by the robust performance of its flagship oncology drug, BRUKINSA®. The company also made strides in reducing its operating loss, achieving non-GAAP operating income for the first time and generating positive cash flows from operations in the latter half of 2024. This financial improvement is underpinned by BRUKINSA's market leadership in Chronic Lymphocytic Leukemia (CLL) in the U.S. and its expanding global reach. The company's strategic focus on a differentiated, wholly-owned hematology franchise with BRUKINSA, sonrotoclax, and its BTK-CDAC asset positions it well for sustained leadership in the $12 billion global CLL market. Beyond hematology, BeiGene is actively developing a deep pipeline in solid tumors, advancing 13 new molecular entities (NMEs) into the clinic in 2024, targeting prevalent cancers like breast, lung, and gastrointestinal cancers. The company's integrated business model, emphasizing internal clinical development capabilities and manufacturing, continues to be a key competitive advantage, enabling faster and more cost-effective development. BeiGene is well-positioned for continued growth and value creation for shareholders.
Financial Highlights
50 data points| Revenue | $3.81B |
| Gross Profit | $3.22B |
| R&D Expenses | $1.95B |
| SG&A Expenses | $1.83B |
| Operating Expenses | $3.78B |
| Operating Income | -$568.20M |
| Interest Expense | $46.89M |
| Net Income | -$644.79M |
| EPS (Basic) | $-0.47 |
| EPS (Diluted) | $-0.47 |
| Shares Outstanding (Basic) | 1.37B |
| Shares Outstanding (Diluted) | 1.37B |
Key Highlights
- 1Achieved $3.8 billion in global revenue for 2024, a 55% increase year-over-year.
- 2BRUKINSA® sales reached $2.6 billion in 2024, demonstrating 105% year-over-year growth.
- 3Reduced GAAP operating loss and achieved positive non-GAAP operating income for the full year 2024.
- 4Generated positive cash flows from operations for the first time in Q3 and Q4 2024.
- 5Advanced 13 differentiated new molecular entities (NMEs) into the clinic in 2024.
- 6Continued to build a deep and innovative solid tumor pipeline with multiple programs advancing.
- 7Entered into a global licensing agreement for SYH2039, a MAT2A inhibitor for solid tumors.